SETTING UP AN RCT TO EVALUATE CANDIDATE VACCINES IN THE CONTEXT OF AN OUTBREAK?

Bruce J Kirenga MBChB, MMed, PhD, FRCP

Principal Investigator
Introduction

An EVD outbreak was declared on 20th Sept 2022
- The outbreak was caused by the Sudan ebolavirus (SUDV) species

Vaccines are an integral part of any disease outbreak response
However, there was none with proven efficacy & safety against the SUDV species at the time of the outbreak
- Only vaccines against EBV were available

There were SUDV candidate vaccines, but these needed to be evaluated in a trial

A ring vaccination trial (Solidarity against Ebola/) was thus initiated to evaluate the efficacy & safety of candidate SUDV species
- With support from WHO & Uganda Ministry of Health
Introduction

The trial was given a local text through a local name: TOKOMEZA Ebola trial

Trial was to evaluate the 3 candidate vaccines

By week 11, the trial was ready to enrol, at least 1 ring was defined_ however this did not happen as the pandemic was controlled

Capacity was established & several lessons learned

We document experiences with Tokomeza Ebola trial set up & highlight factors that facilitated readiness for trial start
Stewardship of the sponsors

Stewardship from WHO & MOH-Uganda

Within the 1st week of outbreak, MOH-Uganda assigned an Investigation team of scientists & implementing organisation (MLI).

WHO provided logistics & supplies.

Regular meetings with the sponsors were held.
Institutional capacity

Inherent capacity to conduct trials during disease outbreaks

MLI had been involved in several COVID-19 studies

Through this capacity had been established
• Human resource (Investigation/scientists, project managers, trialists, trial physicians, QC, finance managers, grants managers etc)
• Existing facilities used (data management, CTU….)

The institute leveraged structures established during COVID-19 & other research studies to support TOKOMEAZ trial processes
Collaborations

North – South: provided scientific oversight
- WHO HQ
- CEPI etc

South – South collaboration
- Created by WHO that included experts from the West African zaire ebolavirus Ebola Virus Vaccine trial (Ebola ca suffit)
- Worked with country team to finalise the protocol & tools
- Worked with country team to train trial teams

In country collaborations
- Makerere University
- Ministry of Health
- Mulago Hospital
- National Medical stores
Ethical & regulatory approvals

Leveraged the Joint scientific & ethical review mechanism for clinical trials

- Brings together all regulators (IRB, NDA, UNCST & Investigators) in one sitting
- This optimized TAT & ensured all ethics & regulatory approvals were obtained within 9 weeks of the outbreak

Involvement of NDA at an early stage helped expedite regulatory approvals for vaccine import & vaccines arrival
Leadership & governance

Immense support at the national level from the sponsors (WHO country office & MoH)

Support from district leadership in outbreak districts (RDC, CAO, DHO….)
  • Availed space
  • Supported community entry

Support from MoH response structures
  • Ebola task forces in the outbreak districts
  • Operating space at Mulago hospital (currently a vaccine house)

Makerere University
  • Administrative & leadership support
In conclusion……………

Narrowing the gap between the onset of an outbreak & the implementation of clinical trials is key

This is possible through stewardship, leveraging prior research experience & multiple stakeholder involvement

But......
• The trial team was able to fast track trial preparations, trial didn’t start by the end of the outbreak

• Missed opportunity of over 100 rings which would have been sufficient to provide at least preliminary efficacy candidate SUDV vaccines

• The current efforts of pre approved, pre assembled teams are probably the solutions to evaluation epidemic MCM
In conclusion

Narrowing the gap between the onset of an outbreak & the implementation of clinical trials is key

This is possible through stewardship, leveraging prior research experience & multiple stakeholder involvement
Thanks